Use of Antidiabetic Drugs in the U.S., 2003–2012

Abstract

Since 2003, the number of adult antidiabetic drug users increased by 42.9% to 18.8 million in 2012. Metformin use increased by 97.0% to 60.4 million prescriptions dispensed in retail pharmacies in 2012. Among antidiabetic drugs newly approved for marketing between 2003 and 2012, the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin had the largest share with 10.5 million prescriptions in 2012. Rosiglitazone use plummeted to <13,000 prescriptions dispensed in retail or mail-order pharmacies in 2012. Concomitancy analyses showed that 44.9% of metformin use was for monotherapy. Between 33.4 and 48.1% of sulfonylurea, DPP-4 inhibitor, thiazolidinedione, and glucagon-like peptide 1 analog use was not accompanied by metformin. CONCLUSIONSThe antidiabetic drug market is characterized by steady increases in volume, and newly approved drugs experienced substantial uptake, especially DPP-4 inhibitors. The use of rosiglitazone has been negligible since restrictions were put in place in 2011. Further study is needed to understand why one-third to one-half of other noninsulin antidiabetic drug use was not concomitant with metformin use despite guidelines recommending that metformin be continued when other agents are added to treatment.In 2010, 18.8 million adults in the U.S. had been diagnosed with diabetes mellitus, 7.0 million additional Americans were affected by undiagnosed diabetes, and an estimated 1.9 million adults received a new diagnosis of diabetes during that year (1). The number of Americans with diabetes who have or have not received a diagnosis is expected to increase to 44

Drug Utilization Evaluation of Antidiabetic Drugs Among Type 2 Diabetes Patients of Tamil Nadu

“…The study documented higher number of DPP-4 inhibitors such as vildagliptin (9.52%) prescribed. DPP-4 inhibitors use has greatly increased with uncontrolled overweight/obese; this result is in agreement with other reports conducted worldwide [12][13][14]. Another study carried out by Tolba et al, vildagliptin as an add-on therapy to gliclazide was not associated with the cardiovascular risks and showed the significant reduction in the hemoglobin A1c and fasting blood sugar [15].…”

A 2-es típusú diabetes antihyperglykaemiás kezelésének alakulása Magyarországon 2001–2014 között – az Országos Egészségbiztosítási Pénztár adatbázis-elemzésének eredményei

“…Nyilvánvaló, hogy ez a tény komoly mérlegelési körülmény, miután 2TDM-ben gyak-ran észlelhető atheroscleroticus eredetű érbetegség, olykor súlyos klinikummal társulva. Tulajdonképpen a terápiás szokások bizonyos átrendeződésének hátterében a roziglitazonnal kapcsolatban 2007-ben leírt cardiovascularis biztonságossági aggály és az azt követő gyógy-szerkivonás is állhatott [30].…”

Evaluación de la prescripción de glibenclamida en diabéticos tipo 2

“…El patrón de prescripción de las sulfonilureas dentro del arsenal terapéutico antidiabético se reporta con porcentajes variables: 26,7 y 56 % en Estados Unidos, 40% en Argentina, 58,2 y 64,9% en Colombia, subrayando que la sulfonilurea evaluada en Argentina y Colombia fue exclusivamente la glibenclamida [5][6][7][8][9] .…”